The Pathophysiology of Coagulopathy in APL

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 2, 2011, Pages 7-9

  Kwaan, Hau C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CD135 ANTIGEN; CD15 ANTIGEN; CD2 ANTIGEN; FIBRINOGEN; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOCORTIN 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; RETINOIC ACID; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CAUSE OF DEATH; DISSEMINATED INTRAVASCULAR CLOTTING; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOGENESIS; LEUKOCYTE COUNT; LUNG HEMORRHAGE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; RISK FACTOR; THROMBOCYTE COUNT; THROMBOPHILIA; THROMBOSIS;

EID: 84856256077     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111:3395-3402.
2. Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol. 2000;108:689-695.
3. Kwaan HC, Huyck T. Thromboembolic and bleeding complications in acute leukemia. Expert Rev Hematol. 2010;3:719-730.
4. Dombret H, Scrobohaci ML, Ghorra P, et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia. 1993;7:2-9.
5. Watanabe R, Murata M, Takayama N, et al. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS). Thromb Haemost. 1997;77:641-645.
6. Tallman MS, Lefebvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost. 2004;2:1341-1350.
7. Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol. 1989;71:511-517.
8. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340:994-1004.
9. Polliack A. Acute promyelocytic leukemia with disseminated intravascular coagulation. Am J Clin Pathol. 1971;56:155-161.
10. Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb Res. 2005;116:109-114.
11. Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4). Blood. 1996;87:613-617.
12. Kwaan HC, Rego EM. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost. 2010;36:917-924.
13. Breccia M, Avvisati G, Latagliata R, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia. 2007;21:79-83.
14. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association. Blood. 1983;61:994-998.
15. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994;84:3843-3849.
16. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood. 1995;86:1072-1081.
17. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75:2112-2117.
18. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237-1243.